75 related articles for article (PubMed ID: 3665670)
21. [Binding of IgG and IgM class antibodies from the serum of patients with ovarian carcinoma to malignant and normal ovaries].
Stankus P; Gazárek F
Cesk Gynekol; 1983 Jun; 48(5):332-8. PubMed ID: 6352065
[No Abstract] [Full Text] [Related]
22. [Preparation and characterization of a monoclonal antibody reactive with human ovarian serous cystadenocarcinoma].
Ookura N
Nihon Gan Chiryo Gakkai Shi; 1987 Feb; 22(1):47-58. PubMed ID: 2440966
[No Abstract] [Full Text] [Related]
23. Tumour-associated antigens for cystadenocarcinoma of the ovary.
Barlow JJ; Bhattacharya M
Clin Obstet Gynaecol; 1983 Aug; 10(2):187-96. PubMed ID: 6413113
[TBL] [Abstract][Full Text] [Related]
24. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
25. Glycoprotein detection using the periodic acid/Schiff reagent: a microassay using microtitration plates.
Devine PL; Warren JA; Layton GT
Biotechniques; 1990 Apr; 8(4):354-6. PubMed ID: 2340167
[No Abstract] [Full Text] [Related]
26. Quantitation of secretory component levels in cyst fluids, ascitic fluids, and sera from ovarian adenocarcinoma patients.
Klein JL; Gall SA; Dawson JR
J Natl Cancer Inst; 1978 Jul; 61(1):57-60. PubMed ID: 209204
[TBL] [Abstract][Full Text] [Related]
27. A comparison of the physicochemical properties of carcinoembryonic antigen in extracts of tumour tissue, ascitic and cyst fluid from ovarian cancer.
Hill R; Daunter B; Magon H; Khoo SK; Mackay EV
Aust J Exp Biol Med Sci; 1981 Aug; 59(4):469-76. PubMed ID: 7295221
[TBL] [Abstract][Full Text] [Related]
28. "Membrane-associated" immunoglobulins in cyst and ascites fluids of ovarian cancer patients.
Taylor DD; Homesley HD; Doellgast GJ
Am J Reprod Immunol (1980); 1983; 3(1):7-11. PubMed ID: 6859379
[TBL] [Abstract][Full Text] [Related]
29. Analysis of sera from ovarian cancer patients for immune complexes.
Witkin SS; Bongiovanni AM; Armbruster T; Birnbaum S; Caputo T
J Clin Lab Immunol; 1984 Jun; 14(2):65-8. PubMed ID: 6748047
[TBL] [Abstract][Full Text] [Related]
30. Detection of malignant ovarian neoplasms: a review of the literature. III. Immunological detection and ovarian cancer-associated antigens.
Smith LH; Oi RH
Obstet Gynecol Surv; 1984 Jun; 39(6):346-60. PubMed ID: 6203071
[TBL] [Abstract][Full Text] [Related]
31. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes.
Ikarashi H; Fujita K; Takakuwa K; Kodama S; Tokunaga A; Takahashi T; Tanaka K
Cancer Res; 1994 Jan; 54(1):190-6. PubMed ID: 8261438
[TBL] [Abstract][Full Text] [Related]
32. Myeloid and lymphoid dendritic cells in the peritoneal fluid of women with ovarian cancer.
Wertel F; Polak G; Roliński J; Barczyński B; Kotarski J
Adv Med Sci; 2006; 51():174-7. PubMed ID: 17357302
[TBL] [Abstract][Full Text] [Related]
33. [Immunochemical study of antigens in the ascitic fluid of patients with ovarian cancer].
Sergeeva NS; Vasil'ev MIu; Avdeev GI
Eksp Onkol; 1986; 8(4):37-40. PubMed ID: 3757883
[TBL] [Abstract][Full Text] [Related]
34. [Soluble interleukin-2 receptor level in the sera and ascitic fluids in patients with ovarian cancer].
Pu FR; Cheng SW; Zhu D
Zhonghua Fu Chan Ke Za Zhi; 1994 Aug; 29(8):478-80, 511. PubMed ID: 7835120
[TBL] [Abstract][Full Text] [Related]
35. Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients.
Stallwood Y; Fisher KD; Gallimore PH; Mautner V
Gene Ther; 2000 Apr; 7(8):637-43. PubMed ID: 10800086
[TBL] [Abstract][Full Text] [Related]
36. Tumor-associated antigen(s) from granulosa cell carcinomas of the ovary.
Bhattacharya M; Barlow JJ; Chu TM; Piver MS
Cancer Res; 1974 Apr; 34(4):818-22. PubMed ID: 4205513
[No Abstract] [Full Text] [Related]
37. High concentrations of activin A in the peritoneal fluid of women with epithelial ovarian cancer.
Cobellis L; Reis FM; Luisi S; Danero S; Pirtoli L; Scambia G; Petraglia F
J Soc Gynecol Investig; 2004 May; 11(4):203-6. PubMed ID: 15120692
[TBL] [Abstract][Full Text] [Related]
38. Factors influencing ovarian cancer survival after chemotherapy.
Webb MJ; Malkasian GD; Jorgensen EO
Obstet Gynecol; 1974 Oct; 44(4):564-70. PubMed ID: 4413425
[No Abstract] [Full Text] [Related]
39. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
40. Studies on xenogenic antisera to tumor-associated antigen of ovarian carcinoma.
Gerber MA; Faiferman I; Cohen CJ; Koffler D
Clin Immunol Immunopathol; 1977 Sep; 8(2):171-80. PubMed ID: 198173
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
